StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.28−0.22 (-2.37%)

Close on Nov 17, 2026Market cap $596.89MP/E –Yield –

Cullinan Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cullinan Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $0, down 100.0% year over year. For fiscal 2022 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$18.94M–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0-100.0%
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$18.94M–

More Cullinan Therapeutics figures

See a number that looks wrong?